Skip to content

US · DCOY · BIOTECHNOLOGY

Decoy Therapeutics Inc. (DCOY) intrinsic value and stock valuation

$0.83as of 2026-11-21 · Mkt cap 2.23M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Decoy Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values DCOY with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DCOY’s statements →

Decoy Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Houston, TX 77021 decoytx.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$0.00
20142025
Net income
-$-12.52M
20142025
Free cash flow
-$-4.83M
20142025
Total equity
$5.89M-23.3% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-12.61M-$-5.73M-$-12.89M-$-31.84M-$-12.81M
Net income-$-12.52M-$-5.58M-$-12.54M-$-31.61M-$-12.77M
EPSd-$-26.08M-$-93M-$-418M-$-1.58B-$-1.28B
Operating cash flow-$-4.83M-$-4.53M-$-12.85M-$-17.6M-$-10.2M
Capital expenditure$0.00$0.00-$0.00-$-1.5M$0.00
Free cash flow-$-4.83M-$-4.53M-$-12.85M-$-19.1M-$-10.2M
Total assets$11.1M$3.02M$6.59M$14.7M$40.8M
Total debt$0.00$220K$290K$0.00$0.00
Net debt-$-10.71M-$-2.21M-$-5.61M-$-12.11M-$-29.21M
Total equity$5.89M$1.51M$5.29M$10.4M$38.7M
Cash and short-term investments$10.7M$2.43M$5.9M$12.1M$29.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$8.52M$0.00$0.00$0.00$0.00
Gross profit-$-8.52M$0.00$0.00$0.00$0.00
Research and development expenses$370K$770K$7.17M$15.8M$8.55M
Selling, general and administrative expenses$3.73M$4.96M$5.72M$7.14M$6.1M
Other expenses$0.00$0.00$0.00$8.87M-$-1.84M
Operating expenses$4.1M$5.73M$12.9M$31.8M$12.8M
Cost and expenses$12.6M$5.73M$12.9M$31.8M$12.8M
Interest income$100K$160K$350K$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$10K$0.00$10K$10K$20K
Ebitda-$-12.51M-$-5.57M-$-12.53M-$-22.97M-$-12.75M
Operating income-$-12.61M-$-5.73M-$-12.89M-$-31.84M-$-12.81M
Total other income/expenses, net$100K$160K$350K$230K$40K
Income before tax-$-12.52M-$-5.58M-$-12.54M-$-31.61M-$-12.77M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-12.52M-$-5.58M-$-12.54M-$-31.61M-$-12.77M
Weighted average shares outstanding$480K$60K$30K$20K$10K
Weighted average diluted shares outstanding$480K$60K$30K$20K$10K
Balance sheet
20252024202320222021
Cash and short-term investments$10.7M$2.43M$5.9M$12.1M$29.2M
Net receivables$0.00$0.00$0.00$1.61M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$11M$2.99M$6.52M$14.5M$30.2M
Property, plant and equipment, net$40K$0.00$0.00$0.00$10K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$8.87M
Long-term investments$0.00$0.00$0.00$0.00$1.61M
Total non-current assets$70K$40K$70K$130K$10.7M
Total assets$11.1M$3.02M$6.59M$14.7M$40.8M
Accounts payable$940K$940K$600K$2.86M$1.54M
Short-term debt$0.00$220K$290K$0.00$0.00
Deferred revenue$3.23M$0.00$0.00$0.00$0.00
Total current liabilities$5.17M$1.51M$1.3M$4.27M$2.11M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$5.17M$1.51M$1.3M$4.27M$2.11M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-94.44M-$-81.92M-$-76.35M-$-63.81M-$-32.2M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$5.89M$1.51M$5.29M$10.4M$38.7M
Total investments$0.00$0.00$0.00$0.00$1.61M
Total debt$0.00$220K$290K$0.00$0.00
Net debt-$-10.71M-$-2.21M-$-5.61M-$-12.11M-$-29.21M
Cash flow statement
20252024202320222021
Net income-$-12.52M-$-5.58M-$-12.54M-$-31.61M-$-12.77M
Depreciation and amortization$10K$0.00$10K$10K$20K
Stock-based compensation$220K$270K$520K$800K$560K
Change in working capital-$-1.05M$770K-$-970K$2.37M$2.03M
Accounts receivable$0.00$0.00$1.48M$0.00$2.25M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.17M$330K-$-2.26M$1.31M-$-310K
Net cash provided by operating activities-$-4.83M-$-4.53M-$-12.85M-$-17.6M-$-10.2M
Investments in property, plant and equipment$0.00$0.00-$0.00$0.00$0.00
Acquisitions, net$1.34M$0.00$0.00$0.00$0.00
Net cash used for investing activities$760K$0.00$0.00-$-1.5M$0.00
Common stock issued$12.6M$1.53M$6.92M$1.99M$27.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.3M$1.06M$6.64M$1.99M$28.3M
Net change in cash$8.28M-$-3.47M-$-6.21M-$-17.11M$18.1M
Cash at end of period$10.7M$2.43M$5.9M$12.1M$29.2M
Operating cash flow-$-4.83M-$-4.53M-$-12.85M-$-17.6M-$-10.2M
Capital expenditure$0.00$0.00-$0.00-$-1.5M$0.00
Free cash flow-$-4.83M-$-4.53M-$-12.85M-$-19.1M-$-10.2M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Decoy Therapeutics Inc.

        Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.

        CEO
        Frederick E. Pierce
        Employees
        11
        Beta
        0.59

        Explore

        Frequently asked questions

        What is the intrinsic value of Decoy Therapeutics Inc. (DCOY)?

        InvestorsCraft does not currently publish an intrinsic value for DCOY. How the IC value is calculated.

        Is DCOY undervalued?

        InvestorsCraft does not publish an undervaluation signal for DCOY at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.